#1 Clinical Trials Search in Europe

Myoviridae Bacteriophage Against Pseudomonas Aeruginosa (92.792 Bp)

This article discusses a clinical trial investigating the use of TP-122A, a bacteriophage cocktail containing Myoviridae Bacteriophage Against Pseudomonas Aeruginosa (92.792 Bp), for treating ventilator-associated pneumonia (VAP). The study aims to assess the safety and tolerability of this innovative treatment approach in addition to standard of care for adult patients with VAP.

Table of Contents

What is MYOVIRIDAE BACTERIOPHAGE?

MYOVIRIDAE BACTERIOPHAGE AGAINST PSEUDOMONAS AERUGINOSA (92.792 BP) is a specific type of virus that targets and kills the bacteria Pseudomonas aeruginosa. It is part of a larger treatment called TP-122, which is a combination of different bacteriophages designed to combat various harmful bacteria[1]. Bacteriophages, or phages for short, are viruses that specifically infect and destroy bacteria without harming human cells.

Target Condition: Ventilator-Associated Pneumonia

This bacteriophage is being studied as a potential treatment for Ventilator-Associated Pneumonia (VAP). VAP is a serious lung infection that can occur in patients who are on mechanical ventilation in hospitals. It’s often caused by bacteria like Pseudomonas aeruginosa, which can be difficult to treat with traditional antibiotics[1].

How It Works

The MYOVIRIDAE BACTERIOPHAGE works by specifically targeting Pseudomonas aeruginosa bacteria. When the phage comes into contact with these bacteria, it attaches to them and injects its genetic material. This causes the bacteria to produce more phages, eventually leading to the destruction of the bacterial cell. This process continues until all the target bacteria are eliminated[1].

Clinical Trial Details

A clinical trial is currently underway to assess the safety and effectiveness of TP-122, which includes this specific bacteriophage. The trial is a Phase 1/2a study, which means it’s one of the earliest stages of testing in humans. The main goals of this trial are to[1]:

  • Evaluate the safety and tolerability of TP-122 when given through nebulization (a method that turns the medication into a fine mist for inhalation)
  • Determine how well TP-122 works in treating VAP compared to standard care alone
  • Assess how TP-122 affects the duration of mechanical ventilation and length of stay in the intensive care unit (ICU)

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria. Some key requirements include[1]:

  • Being 18 years or older
  • Having a confirmed diagnosis of VAP caused by Pseudomonas aeruginosa
  • Meeting specific respiratory and ventilation requirements

There are also several conditions that would exclude a person from participating, such as certain types of cancer, severe asthma, or being immunocompromised.

Safety and Effectiveness

The primary focus of this clinical trial is to assess the safety of TP-122. Researchers will be closely monitoring for any side effects or adverse reactions. They will also be looking at how effective the treatment is by measuring things like[1]:

  • How many patients achieve “Clinical Cure” (improvement of symptoms)
  • How quickly patients improve
  • Whether the treatment successfully eliminates the Pseudomonas aeruginosa bacteria

Administration

In this trial, TP-122 is being administered through nebulization. This means the medication is turned into a fine mist that patients can inhale directly into their lungs. The treatment is given every 8 hours for 7 days, in addition to standard care for VAP[1].

Potential Benefits

While it’s important to note that this treatment is still in the early stages of testing, researchers hope that TP-122, including the MYOVIRIDAE BACTERIOPHAGE, could offer several potential benefits[1]:

  • A new way to treat antibiotic-resistant infections
  • Potentially faster recovery from VAP
  • Possible reduction in the time patients need to be on mechanical ventilation
  • Potential decrease in the length of ICU stays

As research continues, we’ll learn more about how effective and safe this innovative treatment approach may be for patients with Ventilator-Associated Pneumonia.

Aspect Details
Study Type Randomized, Parallel, Open-Label, Phase 1/2a
Condition Ventilator-Associated Pneumonia (VAP)
Intervention TP-122A (bacteriophage cocktail) + Standard of Care
Administration Nebulization every 8 hours for 7 days
Primary Objective Evaluate safety and tolerability of TP-122A
Secondary Objectives Clinical response, microbiological response, mechanical ventilation duration, ICU stay, survival
Key Inclusion Criteria Adults with VAP, P. aeruginosa infection, stable ventilatory requirements
Key Exclusion Criteria Recent cancer treatment, severe respiratory conditions, immunocompromised status
Primary Endpoints Adverse events, laboratory parameters, vital signs, ECG changes
Secondary Endpoints Clinical cure rate, time to cure, microbiological response, ventilator-free days, ICU stay duration

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to evaluate the safety and tolerability of multiple doses of TP-122A, a bacteriophage cocktail, when administered every 8 hours for 7 days in addition to standard of care for adult patients with ventilator-associated pneumonia.
  • Who can participate in this clinical trial? Participants must be 18 years or older, diagnosed with ventilator-associated pneumonia, have stable ventilatory requirements, and a microbiological diagnosis of Pseudomonas aeruginosa infection in the lower respiratory tract. They must also meet other specific inclusion criteria and not fall under any exclusion criteria.
  • How is TP-122A administered in this trial? TP-122A is administered through nebulization, which means it is delivered as a fine mist that can be inhaled directly into the lungs. The treatment is given every 8 hours for 7 days, in addition to standard of care.
  • What are the primary endpoints of the study? The primary endpoints include analyzing adverse events, changes in clinical laboratory parameters, vital signs, and electrocardiogram (ECG) readings. These will be compared between the TP-122A with standard of care group and the standard of care alone group.
  • What are some of the secondary endpoints being measured? Secondary endpoints include the proportion of patients achieving clinical cure, time to clinical cure, microbiological response, number of days on mechanical ventilation, length of ICU stay, and survival rates.

Ongoing Clinical Trials on Myoviridae Bacteriophage Against Pseudomonas Aeruginosa (92.792 Bp)

  • Safety and tolerability study of bacteriophage cocktail TP-122A given by inhalation in adults with ventilator-associated pneumonia

    Not yet recruiting

    2 1 1
    Investigated drugs:
    The Netherlands Portugal

  • Study on the Safety and Tolerability of TP-122 for Treating Ventilator-Associated Pneumonia in Adults

    Not yet recruiting

    2 1 1
    Investigated drugs:
    France

Glossary

  • Ventilator-Associated Pneumonia (VAP): A type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals.
  • Bacteriophage: A virus that infects and replicates within bacteria. In this context, it's being used as a potential treatment for bacterial infections.
  • Myoviridae: A family of viruses that infect bacteria, characterized by their contractile tails.
  • Pseudomonas Aeruginosa: A type of bacteria that can cause infections in humans, particularly in hospital settings and in people with weakened immune systems.
  • Nebulization: The process of converting a liquid into a fine spray or mist, often used to deliver medications directly to the lungs.
  • Standard of Care (SoC): The currently accepted method of treating a particular condition, based on scientific evidence and expert consensus.
  • Clinical Cure: The resolution or significant improvement of signs and symptoms related to the infection, without the need for additional antibiotics.
  • Microbiological Response: The elimination or reduction of the bacteria causing the infection, as determined by laboratory tests.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • ICU: Intensive Care Unit, a special department in a hospital that provides intensive care medicine to critically ill patients.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-tp-122-for-treating-ventilator-associated-pneumonia-in-adults/